drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cell therapy (CAR T cells)
drug_description
An autologous, gene-modified chimeric antigen receptor T-cell (CAR-T) therapy engineered to target GPRC5D on malignant plasma cells in relapsed/refractory multiple myeloma; CAR engagement activates T-cell signaling to drive activation, proliferation, cytokine release, and cytotoxic killing.
nci_thesaurus_concept_id
C206250
nci_thesaurus_preferred_term
Autologous Anti-GPRC5D CAR-T Cells OriCAR-017
nci_thesaurus_definition
A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-GPRC5D CAR-T cells OriCAR-017 specifically recognize and induce selective toxicity in GPRC5D-expressing tumor cells. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation. OriCAR-017 contains a signal activation domain element that may improve CAR-T cells expansion and durability.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor specific for GPRC5D on malignant plasma cells; CAR engagement initiates CD3ΞΆ/costimulatory signaling that activates and expands T cells, drives cytokine release, and induces cytotoxic killing of GPRC5D-positive multiple myeloma cells.
drug_name
OriCAR-017
nct_id_drug_ref
NCT06182696